Fusion Antibodies Ltd
Fusion Antibodies is a high quality CRO that offers a range of royalty free, fee-for-services covering all stages of preclinical therapeutic and diagnostic mabs development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.
Fusion Antibodies wants to use its next generation CDRx humanization antibody technology platform to partner with companies interested in discovering high quality Mab leads against the next generation of therapeutic targets from mouse, rabbit, & rat antibodies. Also of interest are co-development opportunities for innovative therapeutic antibodies or targets. We have humanized >40 novel targets for pharma & biotech clients in Asia, Europe & USA in the past few years.
Fusion Antibodies provides contract services including the custom expression and purification of recombinant proteins for pre-clinical models, antibody sequencing, antibody engineering, antibody humanization, biosimilar development and cGMP services.
Fusion offers CHO and HEK293 cell line expression both in Transient and Stable for research and cGMP scale up.
Fusion Antibodies has the capabilities to act as a one-stop-shop providing its partners with ready-to-develop antibody lead candidates.
Fusion Antibodies is also committed to developing therapeutic antibodies and recombinant proteins to disease specific markers, primarily focused on the key areas of oncology and angiogenesis where immunotherapeutic intervention has a proven track record.
Fusion Antibodies has developed 2 novel humanized oncology drugs the first, Fsn0503 an anti-metastatic, anti-invasive & anti-angiogenic therapeutic antibody targeting Cathepsin S and the second Fsn1006h, a double targeting therapeutic antibody against AREG & HB-EGF ligands, both drug targets are in pre-clinical development and we seek to out licence to advance them to clinical trials.
Dr Paul KerrManaging Director
Glythera Ltd is a biotechnology company specializing in the development of platform technologies for next generation biotherapeutics with 2 core programmes:- PermaLink™ - a novel, stable, highly cysteine-specific conjugation platform for antibody drug conjugates (ADCs). PermaLink™ is associated with enhanced anti-tumour activity in vivo vs maleimide in comparative ADC models. It is suitable for cleavable and non-cleavable systems - PermaCarb™ - a novel sialylation correction platform which can (i) improve bioavailability & enhance product performance and (ii) remove the issue of sialic acid contamination. It is particularly appropriate for the development of biobetters and biosimilars. PermaCarb™ has been validated vs several biotherapeutics, including FSH and etanercept. Based in the NE of England, Glythera has dedicated bioprocessing and chemistry laboratories enabling us to conduct in-house evaluations for our partners to progress applications of PermaLink™ and PermaCarb™ technologies. We are seeking license collaborations for PermaLink™ and out-license partners for PermaCarb™.
Dr David SimpsonChief Executive Officer
Horizon Discovery Group plc
Horizon powers genomic research and translational medicine from sequence to treatment.
Horizon Discovery is a UK Biotechnology company founded in 2007, and built upon a 20 year heritage in oncology research, translational medicine and gene-editing. The company’s unique history and experience has culminated in a precision gene-editing platform that incorporates rAAV, CRISPR and ZFN technologies. Horizon is the only company that has access to such a broad range of tools, allowing any genome modification challenge to be addressed.
Mr Kam DhaliwalSenior VP of Global Business
IDACO Consulting Limited
Strategic pharmaceutical and pre-clinical consulting services.
Undertaking due diligences on behalf of organisations in- and out- licensing development drug candidates.
Critical due diligence, rationalisation and evaluation of IP portfolios and early-stage/preclinical projects - ultimately looking to de-risk projects and increase commercial attractiveness and licensing potential.
Undertaking commercial evaluations and preparing value propositions for early-stage projects.
Translational development support to academia, bridging ideas and projects into commercially attractive proposals.
Advising and supporting academic institutions, start-ups and SMEs on out-sourcing strategies - looking for timely, cost-effective solutions and accelerating the speed of progression and completion of projects.
Oversight and management of outsourced CMC and preclinical projects.
Exploring innovative business models and opportunities for funding between academia and the out-sourcing network, looking to create collaborative win-win partnerships to progress projects.
Mr Ian CoxDirector
Illingworth Research Ltd
Illingworth Research is a full service clinical CRO with experience across all phases of development from Phase I / proof of concept studies to post-marketing studies for small molecules, biotechnology products, medical devices and diagnostics. With a network of clinical infrastructure covering most therapeutic areas varying from clinical research units, primary, secondary and tertiary care sites across Europe and with partners in North America and Australasia, Illingworth has the capability to deliver large multi-centre global studies on time and within budget. Illingworth also provides research nurses for patient homecare to support studies for optimisation of patient retention and compliance. Illingworth also offers a medical photography service.
Dr Julian CooperDirector of Business Development and Proposals
KWS BioTest Ltd.
KWS BioTest is a cutting edge CRO which works closely with clients to develop lead compounds as novel treatments for human disease. Our staff are specialists in the fields of infection, inflammation, immunology and pain, and can therefore help you with model selection, study design and data interpretation in order to maximise value to your programmes. We offer a wide range of validated models to enable your target validation, hit-to-lead and lead optimisation programmes, as well as clinical biomarker analysis. We routinely undertake bespoke assay development in order to better support customer projects.
Dr Leann QuinnHead of Sales
MGB Biopharma Ltd
MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise.
Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens. Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.
MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections.
MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.
Mr Raymond SpencerCFO
Dr Miroslav RavicCEO
Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. We are advancing a pipeline of novel clinical and pre-clinical product candidates based on our proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and neuroscience/ophthalmology.
Our strategy is to develop our own products in-house in rare cancers and with partners in other indications, and to accelerate growth of the business through strategic acquisition of complementary products and technologies. We are particularly interested in opportunities in the Oncology area.
Our Octreotide product is available for licensing, and we have several ophthalmology programmes underway. In addition, we have multiple collaborations and partners, and a joint venture in Diabetes with a Transbuccal insulin in Phase 2.
Our technology is unique and has created possibly the smallest biomedical particles in the clinic today.
Dr Tim SpareyBusiness Development Officer
Dr Simon BennettBusiness Development Consultant
Neem Biotech Ltd
Neem Biotech is a rapidly growing biotechnology company developing novel antimicrobials that are derived from plant and marine sources. Once extracted, purified and stabilised, these bioactive compounds are further developed in-house into platform technologies that target important human, animal and plant health markets, including areas of high unmet medical needs such as antimicrobial resistance and rare diseases. Particular areas of interest for Neem Biotech include cystic fibrosis, wound healing and fatty liver disease.
We are currently in preparation for a Phase 1 clinical trial looking at the effectiveness of our lead compound as a potential new treatment for pseudomonas-caused respiratory infections in adults with Cystic Fibrosis.
Neem Biotech is also developing a number of products for animal and plant health applications. These products are expected to be commercialised via partners starting in 2016.
Neem Biotech is based in Blaenau Gwent, Wales, UK
Dr Gareth EvansR&D Coordinator
Scottish Development International
Scottish Development International is a government-funded organisation which provides access to key Scottish product and service companies in the life sciences, together with research and clinical expertise from Scottish Universities and Research Institutes and financial support programs to support your development.
Scotland’s life sciences sector consists of over 650 organisations employing over 32,500 people and is one of the world's leading centers for stem cell research and regenerative medicine. Scotland has built a reputation as one of Europe's leading locations for the development of new tools and technologies, as well as the clinical assessment of new cell-based therapies. These strengths are based on the connectivity of the translational, clinical, analytical and regulatory support mechanisms.